Literature DB >> 22289435

The impact of ageing on the barriers to drug delivery.

Yvonne Perrie1, Raj K Singh Badhan, Daniel J Kirby, Deborah Lowry, Afzal R Mohammed, Defang Ouyang.   

Abstract

Generally, we like to see ageing as a process that is happening to people older than ourselves. However the process of ageing impacts on a wide range of functions within the human body. Whilst many of the outcomes of ageing can now be delayed or reduced, age-related changes in cellular, molecular and physiological functionality of tissues and organs can also influence how drugs enter, distribute and are eliminated from the body. Therefore, the changing profile of barriers to drug delivery should be considered if we are to develop more age-appropriate medicines. Changes in the drug dissolution and absorption in older patients may require the formulation of oral delivery systems that offer enhanced retention at absorption sites to improve drug delivery. Alternatively, liquid and fast-melt dosage systems may address the need of patients who have difficulties in swallowing medication. Ageing-induced changes in the lung can also result in slower drug absorption, which is further compounded by disease factors, common in an ageing population, that reduce lung capacity. In terms of barriers to drug delivery to the eye, the main consideration is the tear film, which like other barriers to drug delivery, changes with normal ageing and can impact on the bioavailability of drugs delivery using eye drops and suspensions. In contrast, whilst the skin as a barrier changes with age, no significant difference in absorption of drugs from transdermal drug delivery is observed in different age groups. However, due to the age-related pharmacokinetic and pharmacodynamic changes, dose adaptation should still be considered for drug delivery across the skin. Overall it is clear that the increasing age demographic of most populations, presents new (or should that be older) barriers to effective drug delivery.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22289435     DOI: 10.1016/j.jconrel.2012.01.020

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  7 in total

Review 1.  Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.

Authors:  Jens Markus Borghardt; Benjamin Weber; Alexander Staab; Charlotte Kloft
Journal:  AAPS J       Date:  2015-04-07       Impact factor: 4.009

2.  How useful are medication patient information leaflets to older adults? A content, readability and layout analysis.

Authors:  Fang Liu; Sarah Abdul-Hussain; Shams Mahboob; Vijay Rai; Andrzej Kostrzewski
Journal:  Int J Clin Pharm       Date:  2014-07-02

3.  Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.

Authors:  Jens Markus Borghardt; Benjamin Weber; Alexander Staab; Christina Kunz; Charlotte Kloft
Journal:  Br J Clin Pharmacol       Date:  2016-06-23       Impact factor: 4.335

4.  Preparation, Evaluation and Bioavailability Studies of Eudragit Coated PLGA Nanoparticles for Sustained Release of Eluxadoline for the Treatment of Irritable Bowel Syndrome.

Authors:  Md K Anwer; Ramadan Al-Shdefat; Essam Ezzeldin; Saad M Alshahrani; Abdullah S Alshetaili; Muzaffar Iqbal
Journal:  Front Pharmacol       Date:  2017-11-20       Impact factor: 5.810

5.  Preparation and Characterization of Loperamide-Loaded Dynasan 114 Solid Lipid Nanoparticles for Increased Oral Absorption In the Treatment of Diarrhea.

Authors:  Lili Wei; Yunfang Yang; Kun Shi; Jun Wu; Wei Zhao; Jingxin Mo
Journal:  Front Pharmacol       Date:  2016-09-21       Impact factor: 5.810

6.  Prevalence of and risk factors for adverse events in Alzheimer's patients receiving anti-dementia drugs in at-home care.

Authors:  Hirohisa Imai; Takuya Hirai; Ryosuke Kumazawa; Shunsaku Nakagawa; Atsushi Yonezawa; Kazuo Matsubara; Hiroyuki Nakao
Journal:  PLoS One       Date:  2020-04-06       Impact factor: 3.240

7.  The Fate of Sialic Acid and PEG Modified Epirubicin Liposomes in Aged versus Young Cells and Tumor Mice Models.

Authors:  Dezhi Sui; Xianmin Meng; Changzhi Li; Xueying Tang; Ying Qin; Ning Zhang; Junqiang Ding; Xinrong Liu; Yihui Deng; Yanzhi Song
Journal:  Pharmaceutics       Date:  2022-02-28       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.